The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2023 | The unmet needs of patients with MCL who relapse after CAR-T
Preetesh Jain, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the poor outcomes of patients with mantle cell lymphoma (MCL) who relapse following CAR-T therapy. Dr Jain comments on the potential benefit of new treatment approaches, such as first-line CAR-T and combination therapies using novel agents, and highlights the need for a better understanding of the factors that lead to CAR-T resistance. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultant or advisory role: Kite, Eli Lilly, Loxo oncology
Honoraria: Aptitude health, pharmacy times
Research funding: Astra Zeneca, Kite, beigene
Educational grants: Dava oncology
